SCHEMBL6449306

SCHEMBL6449306

CCC(C)(C)c1cc(-c2ccc(C=C3SC(=O)NC3=O)cn2)cc(N)c1O

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.47
PTGS2 P35354 1/20 0.47
RAB9A P51151 2/20 0.44
NPC1 O15118 1/20 0.44
HTT P42858 1/20 0.44
PIM1 P11309 4/20 0.44
PIM2 Q9P1W9 4/20 0.44
PIM3 Q86V86 1/20 0.44
NAT1 P18440 1/20 0.42
IGF1R P08069 4/20 0.42
AKR1B1 P15121 3/20 0.42
GSK3B P49841 2/20 0.41
HPGD P15428 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
CISD1 Q9NZ45 1/20 0.40
MAOA P21397 1/20 0.40
MAOB P27338 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6449303 1.00 PTGS1 (0.47) PTGS1PTGS2RAB9ANPC1HTT
SCHEMBL6451356 0.85 GSK3B (0.49) PTGS1PTGS2RAB9ANPC1HTT
SCHEMBL6451359 0.85 GSK3B (0.49) PTGS1PTGS2RAB9ANPC1HTT
SCHEMBL6449258 0.85 PIM1 (0.51) PTGS1PTGS2RAB9ANPC1HTT
SCHEMBL6449261 0.85 PIM1 (0.51) PTGS1PTGS2RAB9ANPC1HTT
SCHEMBL6449159 0.81 NPC1 (0.43) PTGS1PTGS2RAB9ANPC1HTT
SCHEMBL6449163 0.81 NPC1 (0.43) PTGS1PTGS2RAB9ANPC1HTT
SCHEMBL6450520 0.78 NPC1 (0.41) PTGS1PTGS2RAB9ANPC1HTT
SCHEMBL6450518 0.78 NPC1 (0.41) PTGS1PTGS2RAB9ANPC1HTT
SCHEMBL6450595 0.78 HPGD (0.48) RAB9ANPC1HTTAKR1B1GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014767-A1 Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases INCYTE CORPORATION 2005-01-20 US disclosed
WO-2004066952-A2 BENZOXAZOLE, BENZOTHIAZOLE, AND BENZIMIDAZOLE DERIVATIVES FOR THE TREATMENT OF CANCER AND OTHER DISEASES INCYTE CORPORATION (US) 2004-08-12 WO disclosed
EP-1373216-A1 4,5-DIHYDRO-1H-PYRAZOLE DERIVATIVES HAVING CB1-ANTAGONISTIC ACTIVITY Solvay Pharmaceuticals B.V. (NL) 2004-01-02 EP disclosed
WO-2002076949-A1 4,5-DIHYDRO-1H-PYRAZOLE DERIVATIVES HAVING CB1-ANTAGONISTIC ACTIVITY SOLVAY PHARMACEUTICALS B.V. (NL) 2002-10-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014767-A1 Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases AR, CCNT1, BRD1 PTGS1 469/4885PTGS2 795/4885RAB9A 3637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.